NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

NCT05549323

TerminatedPhase 1

Sponsor: Pfizer

Conditions: Ulcerative Colitis

Interventions: PF-07054894, Placebo

Countries: United States, Germany, Poland

This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Confirmed diagnosis of moderate to severe (Part A) or mild to moderate (Part B) UC for ≥3 months prior to baseline.
* Active disease beyond the rectum (\>15 cm of active disease from the anal verge at the screening endoscopy).

Part A (moderate to severe): Must have a 5 to 9 score on the modified mayo score, including an endoscopy subscore of at least 2. Part B (mild to moderate): Participants with mMS of 4 to 6, ES of ≥2 and RB score of ≥1

* Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.
* Total body weight \>40 kg (88.2 lb).

Exclusion Criteria:

* Presence of indeterminate; microscopic; ischemic; infectious; radiation colitis; diverticular disease; Crohn's disease; colonic stricture; colonic obstruction/ resection; presence of cancer.
* History of bowel surgery within 6 months prior to baseline.
* History of significant trauma or major surgery within 4 weeks of screening or considered in imminent need of surgery or with elective surgery scheduled to occur during the study.
* Presence of clinical signs of fulminant colitis or toxic megacolon, primary sclerosing cholangitis and evidence of colonic dysplasia, adenomas or neoplasia.
* Clinically significant infections within 6 months of baseline
Locations (17)
  • Kissimmee, Florida, United States
  • Kissimmee, Florida, United States
  • Kissimmee, Florida, United States
  • Tampa, Florida, United States
  • Tampa, Florida, United States
  • Iowa City, Iowa, United States
  • San Antonio, Texas, United States
  • Berlin, Germany
  • Berlin, Germany
  • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
  • Krakow, Lesser Poland Voivodeship, Poland
  • Warsaw, Masovian Voivodeship, Poland
  • Bialystok, Podlaskie Voivodeship, Poland
  • Knurów, Silesian Voivodeship, Poland
  • Elblag, Warmian-Masurian Voivodeship, Poland
  • Lodz, Poland
  • Piotrkow Trybunalski, Łódź Voivodeship, Poland